Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis
- Registration Number
- NCT03624127
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 666
- Plaque psoriasis for at least 6 months
- Moderate to severe disease
- Candidate for phototherapy or systemic therapy
- Other forms of psoriasis
- History of recent infection
- Prior exposure to BMS-986165 or active comparator
Other protocol defined inclusion/exclusion criteria apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo - BMS-986165 BMS-986165 - Apremilast Apremilast -
- Primary Outcome Measures
Name Time Method The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (sPGA 0/1) Week 16 The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. The higher sPGA score denotes to more severe disease activity (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; Severe = 4). sPGA 0/1 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as 0 or 1 with at least 2-point improvement from baseline using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 16 or who have missing week 16 endpoint data for any reason.
The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (PASI 75) Baseline and Week 16 PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 16 or who have missing week 16 endpoint data for any reason.
Baseline is defined as the measurement at the randomization visit (Week 0).
- Secondary Outcome Measures
Name Time Method The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremilast at Week 16 (sPGA 0/1) Week 16 The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. The higher sPGA score denotes to more severe disease activity (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; Severe = 4). sPGA 0/1 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as 0 or 1 with at least 2-point improvement from baseline using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 16 or who have missing week 16 endpoint data for any reason.
The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremilast at Week 24 (sPGA 0/1) Week 24 The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. The higher sPGA score denotes to more severe disease activity (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; Severe = 4). sPGA 0/1 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as 0 or 1 with at least 2-point improvement from baseline using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 24 or who have missing week 24 endpoint data for any reason.
The Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score at Week 16 (PASI 90) Baseline and Week 16 PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the response as a number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 16 or who have missing week 16 endpoint data for any reason.
Baseline is defined as the measurement at the randomization visit (Week 0).Change From Baseline in Psoriasis Symptoms and Signs Diary (PSSD) Symptom Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 16 Baseline and Week 16 PSSD is an 11-item participant-reported instrument that assesses severity of symptoms and participant-observed signs commonly associated in plaque psoriasis. PSSD assesses severity of 5 symptoms (itch, pain, stinging, burning, skin tightness) and 6 participants-observed signs (skin dryness, cracking, scaling, shedding or flaking, redness, bleeding) using 0-10 numerical ratings. The severity of each item is rated on an 11-point numeric rating scale ranging from 0 (absent) to 10 (worst imaginable). A symptom score will be derived by averaging the 5 questions and multiplying by 10. A sign score will be derived by averaging the 6 questions and multiplying by 10. A total PSSD score with range 0-100 will be derived from taking the average of the symptom and sign scores, where 0 representing the least severe symptom/sign and 100 the most severe. A mBOCF approach will be used for missing data.
Baseline is defined as the measurement at the randomization visit (Week 0).Number of Participants With a Physician's Global Assessment-Fingernails (PGA-F) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 Week 16 PGA-F overall condition of the fingernails is rated on a 5-point scale (0 = clear; 1 = minimal; 2 = mild; 3 = moderate; and 4 = severe). PGA-F 0/1 is the response as a number of participants with a PGA-F score of 0 or 1 with at least a 2-point improvement from baseline among participants with a baseline PGA-F score \>=3.
The Number of Participants With a Scalp Specific Physician's Global Assessment (Ss-PGA) Score 0 or 1 at Week 16 (Ss-PGA 0/1) Week 16 ss-PGA is a 5-point scale that evaluates scalp lesions in terms of clinical signs of redness, thickness, and scaliness. The higher ss-PGA score denotes to more severe disease activity (0 = absence of disease; 1 = very mild disease; 2 = mild disease; 3 = moderate disease; 4 = severe disease). ss-PGA 0/1 is the response as a number of participants who experience a ss-PGA score that determines scalp lesions severity as 0 or 1 with at least a 2-point improvement from baseline among participants with a baseline ss-PGA score \>=3.
The Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 24 (PASI 90) Baseline and Week 24 PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the response as a number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 24 or who have missing week 24 endpoint data for any reason.
Baseline is defined as the measurement at the randomization visit (Week 0).The Number of Participants Who Achieve a 100% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (PASI 100) Baseline and Week 16 PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 100 is the response as a number of participants who experience at least a 100% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 16 or who have missing week 16 endpoint data for any reason.
Baseline is defined as the measurement at the randomization visit (Week 0).The Number of Participants With a Static Physician's Global Assessment Score of 0 at Week 16 (sPGA 0) Week 16 The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. The higher sPGA score denotes to more severe disease activity (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). sPGA 0 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as 0 using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 16 or who have missing week 16 endpoint data for any reason.
Psoriasis Symptoms and Signs Diary (PSSD) Symptom Score 0 at Week 16 Week 16 PSSD with a 24-hour recall period is an 11-item participant-reported instrument that assesses severity of symptoms and participant-observed signs commonly associated in plaque psoriasis. PSSD assesses severity of 5 symptoms (itch, pain, stinging, burning, skin tightness) and 6 participants-observed signs (skin dryness, cracking, scaling, shedding or flaking, redness, bleeding) using 0-10 numerical ratings. The severity of each item is rated on an 11-point numeric rating scale ranging from 0 (absent) to 10 (worst imaginable). PSSD 0 is the response as a number of participants who experience a PSSD symptom score that is derived from the average of the scores and determines psoriasis severity as 0 among participants with a baseline PSSD symptom score \>= 1.
The Number of Participants With a Dermatology Life Quality Index (DLQI) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (DLQI 0/1) Week 16 DLQI is a participant-reported quality of life index which consists of 10 questions concerning symptoms and feelings, daily activities, leisure, work, school, personal relationships, and treatment during the last week before questionnaire. Each question is scored on a scale of 0 to 3 by a tick box (0 = "not at all"; 1 = "a little"; 2 = "a lot"; or 3 = "very much"). The scores are summed, giving a range from 0 (no impairment of life quality) to 30 (maximum impairment). DLQI 0/1 is the response as a number of participants who experience DLQI score of 0 or 1 among participants with a baseline DLQI score \>=2.
The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 16 (PASI 75) Baseline and Week 16 PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 16 or who have missing week 16 endpoint data for any reason.
Baseline is defined as the measurement at the randomization visit (Week 0).The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 24 (PASI 75) Baseline and Week 24 PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 24 or who have missing week 24 endpoint data for any reason.
Baseline is defined as the measurement at the randomization visit (Week 0).The Number of Participants Who Achieve a 75% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 52 and at Week 24 (PASI 75) Baseline, Week 52 and Week 24 PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75 is the response as a number of participants who experience at least a 75% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 52, or who have missing week 52 endpoint data for any reason.
Baseline is defined as the measurement at the randomization visit (Week 0).The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Apremilast at Week 52 and at Week 24 (sPGA 0/1) Week 52 and Week 24 The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scale, and induration. The average of the 3 scales, which is rounded to the nearest whole number, is the final sPGA score. The higher sPGA score denotes to more severe disease activity (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; Severe = 4). sPGA 0/1 is the response as a number of participants who experience a sPGA score that determines psoriasis severity as 0 or 1 with at least 2-point improvement from baseline using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 52 or who have missing week 52 endpoint data for any reason.
The Number of Participants Who Achieve a 90% Improvement From Baseline in the Psoriasis Area and Severity Index (PASI) Score in Participants Receiving BMS-986165 Compared to Apremilast at Week 52 and at Week 24 (PASI 90) Baseline, Week 52 and Week 24 PASI is a measure of the average redness, thickness, and scaliness of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 90 is the response as a number of participants who experience at least a 90% improvement in PASI score as compared with the baseline value using the non-responder imputation (NRI) method that will be used for participants who discontinue treatment or study prior to week 52, or who have missing week 52 endpoint data for any reason.
Baseline is defined as the measurement at the randomization visit (Week 0).
Trial Locations
- Locations (153)
Keck School of Medicine
🇺🇸Los Angeles, California, United States
Sapporo Skin Clinic
🇯🇵Sapporo, Hokkaido, Japan
DermoDent - Centrum Medyczne Czajkowscy
🇵🇱Osielsko, Poland
Local Institution - 0203
🇵🇱Wroclaw, Poland
Local Institution - 0160
🇯🇵Osaka, Japan
Local Institution - 0191
🇵🇱Warszawa, MZ, Poland
Centrum Medyczne All-Med
🇵🇱Lodz, Poland
Clinical Research Group
🇵🇱Warszawa, Poland
Center for Clinical Studies - Texas Medical Center
🇵🇱Wroclaw, Poland
Lukasz Matusiak 4health
🇵🇱Wroclaw, Poland
dermMedica Sp. z o.o.
🇵🇱Wroclaw, Poland
Local Institution - 0131
🇷🇺Ekaterinburg, Russian Federation
MUZ Clinical Hospital of Emergency Medical Care n.a. N.V. Soloviev
🇷🇺Yaroslavl, Russian Federation
Synexus Clinical Research - Anderson
🇺🇸Anderson, South Carolina, United States
University California at Irvine Dermatology Clinical Research Center
🇺🇸Irvine, California, United States
DermCare Experts
🇺🇸Quincy, Massachusetts, United States
PMG Research of Charlotte
🇺🇸Charlotte, North Carolina, United States
The South Bend Clinic
🇺🇸South Bend, Indiana, United States
First OC Dermatology & Belle-Aimee Skincare Clinic Fountain Valley
🇺🇸Fountain Valley, California, United States
Dream Team Clinical Research
🇺🇸Pomona, California, United States
Precision Clinical Research
🇺🇸Davie, Florida, United States
Unison Clinical Trials
🇺🇸Sherman Oaks, California, United States
Associated Skin Care Specialists - Minnesota Clinical Study Center
🇺🇸New Brighton, Minnesota, United States
The Ohio State University Wexner Medical Center
🇺🇸Columbus, Ohio, United States
Ameriderm Research
🇺🇸Ormond Beach, Florida, United States
Mount Sinai - Queens
🇺🇸New York, New York, United States
Springfield Clinic
🇺🇸Springfield, Illinois, United States
Local Institution - 0169
🇯🇵Yokohama, Kanagawa, Japan
San Marcus Research Clinic
🇺🇸Miami Lakes, Florida, United States
Kurashiki Central Hospital
🇯🇵Kurashiki, Okayama, Japan
Dermatology Treatment and Research Center
🇺🇸Dallas, Texas, United States
Local Institution - 0188
🇯🇵Shinagawa, Tokyo, Japan
Hamilton Dermatology
🇺🇸Alpharetta, Georgia, United States
Austin Institute for Clinical Research - Pflugerville
🇺🇸Pflugerville, Texas, United States
Clinical Research Center of Reading
🇺🇸Wyomissing, Pennsylvania, United States
Local Institution - 0165
🇯🇵Nagoya, Aichi, Japan
Local Institution - 0181
🇯🇵Toon-Shi, Ehime, Japan
Kobe University Hospital
🇯🇵Kobe, Hyogo, Japan
Renstar Medical Research
🇺🇸Ocala, Florida, United States
The Dermatology Center
🇺🇸New Albany, Indiana, United States
Clinical Trials of America - Monroe
🇺🇸Monroe, Louisiana, United States
Dr. Chih-ho Hong Medical Inc.
🇨🇦Surrey, British Columbia, Canada
Forest Hills Dermatology Group
🇺🇸Kew Gardens, New York, United States
Local Institution
🇨🇳Taipei, Taiwan
Kirk Barber Research
🇨🇦Calgary, Alberta, Canada
Skin Centre for Dermatology
🇨🇦Peterborough, Ontario, Canada
University of Occupational and Environmental Health, Japan
🇯🇵Kitakyushu, Fukuoka, Japan
Jichi Medical University Hospital
🇯🇵Shimotsuke, Tochigi, Japan
Palm Beach Research Center
🇺🇸West Palm Beach, Florida, United States
Synexus - Columbus
🇺🇸Columbus, Ohio, United States
Interspond - Stones River Dermatology - Murfreesboro Office
🇺🇸Murfreesboro, Tennessee, United States
Klinische Forschung Dresden GmbH
🇩🇪Dresden, Germany
XLR8 Medical Research
🇨🇦Windsor, Ontario, Canada
Deaconess Clinic Downtown
🇺🇸Evansville, Indiana, United States
The Indiana Clinical Trials Center
🇺🇸Plainfield, Indiana, United States
Interspond - Acclaim Dermatology
🇺🇸Sugar Land, Texas, United States
Docteur David Gratton Dermatologue
🇨🇦Montreal, Quebec, Canada
Siena Medical Research
🇨🇦Montreal, Quebec, Canada
Kochi Medical School Hospital
🇯🇵Nakoku, Kochi, Japan
Eastern Washington Dermatology
🇺🇸Walla Walla, Washington, United States
North Bay Dermatology Centre
🇨🇦North Bay, Ontario, Canada
Fukuoka University Hospital
🇯🇵Fukuoka-shi, Fukuoka, Japan
Local Institution - 0182
🇯🇵Isehara City, Kanagawa, Japan
Hospital Universitario de Fuenlabrada
🇪🇸Madrid, Spain
The Guenther Dermatology Research Centre
🇨🇦London, Ontario, Canada
Local Institution - 0140
🇷🇺Moscow, Russian Federation
Local Institution - 0201
🇵🇱Bialystok, Poland
Local Institution - 0187
🇰🇷Hwaseong-si, Korea, Republic of
Local Institution - 0144
🇵🇱Gdynia, Poland
Local Institution - 0079
🇵🇱Krak, Poland
Solumed Centrum Medyczne
🇵🇱Poznan, Poland
Local Institution - 0121
🇪🇸Alcorcon, Spain
Synexus - Katowice
🇵🇱Katowice, Poland
Hospital Universitario Cruces
🇪🇸Barakaldo, Spain
Kyoto University Hospital
🇯🇵Kyoto, Japan
Centrum Terapii Wspolczesnej
🇵🇱Lodz, Poland
Local Institution - 0200
🇵🇱Poznan, Poland
Local Institution - 0172
🇷🇺Krasnodar, Russian Federation
Miejski Szpital Zespolony w Olsztynie
🇵🇱Olsztyn, Poland
Newcastle upon Tyne Hospitals NHS Foundation Trust
🇬🇧Newcastle Upon Tyne, United Kingdom
Azbuka Zdorovya Medical Center
🇷🇺Kazan, Russian Federation
State budgetary institution of Ryazan region - Regional Clinical Skin and Venereal Dispensary
🇷🇺Ryazan, Russian Federation
Clinic of Skin Diseases of Pierre Wolkenstein
🇷🇺Saint Petersburg, Russian Federation
Saint-Petersburg SBHI Dermatological and Venereological Dispensary No. 10 - Clinic of Dermatology
🇷🇺Saint Petersburg, Russian Federation
Local Institution - 0097
🇪🇸Valencia, Spain
Hospital Universitario La Paz
🇪🇸Madrid, Spain
Hospital Universitari Germans Trias i Pujol
🇪🇸Badalona, Spain
LCC Medical Research
🇺🇸Miami, Florida, United States
International Dermatology Research
🇺🇸Miami, Florida, United States
Well Pharma Medical Research
🇺🇸Miami, Florida, United States
Miami Dade Medical Research Institute
🇺🇸Miami, Florida, United States
University of Pittsburgh Medical Center
🇺🇸Pittsburgh, Pennsylvania, United States
University Dermatology Group
🇺🇸San Diego, California, United States
University of Texas Health Science Center at San Antonio
🇺🇸San Antonio, Texas, United States
Duke University Health System - Duke Clinic
🇺🇸Durham, North Carolina, United States
Kansas City Dermatology
🇺🇸Overland Park, Kansas, United States
Wiseman Dermatology Research
🇨🇦Winnipeg, Manitoba, Canada
New England Research Associates
🇺🇸Bridgeport, Connecticut, United States
Indago Research and Health Center
🇺🇸Hialeah, Florida, United States
Healthcare Research Network - Flossmoor
🇺🇸Flossmoor, Illinois, United States
ActivMed Practices and Research - Beverly
🇺🇸Beverly, Massachusetts, United States
Somerset Skin Centre
🇺🇸Troy, Michigan, United States
MediSearch Clinical Trials
🇺🇸Saint Joseph, Missouri, United States
Menter Dermatology Research Institute
🇺🇸Dallas, Texas, United States
Dermatology Associates of Seattle
🇺🇸Seattle, Washington, United States
Center for Clinical Studies - Webster
🇺🇸Webster, Texas, United States
Hamamatsu University Hospital
🇯🇵Hamamatsu, Shizuoka, Japan
Teikyo University Hospital
🇯🇵Itabashi-Ku, Tokyo, Japan
Kumamoto University Hospital
🇯🇵Kumamoto, Japan
Klinika Kozhnykh I Venericheskikh Bolezney
🇷🇺Saratov, Russian Federation
Smolensk State Medical University
🇷🇺Smolensk, Russian Federation
Hospital del Mar - Parc de Salut Mar
🇪🇸Barcelona, Spain
MAC Clinical Research - Blackpool
🇬🇧Lancashire, United Kingdom
Synexus - Manchester Clinical Research Centre
🇬🇧Manchester, United Kingdom
Salford Royal NHS Foundation Trust
🇬🇧Manchester, United Kingdom
MAC Clinical Research - Liverpool
🇬🇧Prescot, United Kingdom
Achieve Clinical Research
🇺🇸Birmingham, Alabama, United States
Elite Clinical Studies
🇺🇸Phoenix, Arizona, United States
Arizona Research Center
🇺🇸Phoenix, Arizona, United States
Health Research of Oklahoma
🇺🇸Oklahoma City, Oklahoma, United States
Oregon Medical Research Center
🇺🇸Portland, Oregon, United States
Synexus - Merseyside Clinical Research Centre
🇬🇧Liverpool, United Kingdom
Guys and Saint Thomas NHS Foundation Trust
🇬🇧London, United Kingdom
Office of Dr. Arnon Moshe Katz
🇨🇦Newmarket, Ontario, Canada
Institute of Cosmetic and Laser Surgery
🇨🇦Oakville, Ontario, Canada
The Centre for Dermatology - Richmond Hill
🇨🇦Richmond Hill, Ontario, Canada
Centre de Recherche Dermatologique du Quebec Metropolitain
🇨🇦Quebec, Canada
Coastal Clinical Research - Mobile
🇺🇸Mobile, Alabama, United States
Charite Universitatsmedizin Berlin
🇩🇪Berlin, Germany
M3 Wake Research, Inc.
🇺🇸Raleigh, North Carolina, United States
Metroplex Clinical Research Center
🇺🇸Dallas, Texas, United States
Dartmouth-Hitchcock Medical Center
🇺🇸Lebanon, New Hampshire, United States
Olympian Clinical Research
🇺🇸Tampa, Florida, United States
Clinical Research Center of the Carolinas
🇺🇸Charleston, South Carolina, United States
Westlake Dermatology - Westlake
🇺🇸Austin, Texas, United States
David Fivenson MD Dermatology
🇺🇸Ann Arbor, Michigan, United States
Hassman Research Institute
🇺🇸Berlin, New Jersey, United States
Synexus - Tucson
🇺🇸Tucson, Arizona, United States
Hull Dermatology
🇺🇸Rogers, Arkansas, United States
National Hospital Organization Yokohama Medical Center
🇯🇵Yokohama-shi, Kanagawa, Japan
University Hospital - Kyoto Preferctural University of Medicine
🇯🇵Kyoto-city, Kyoto, Japan
Mie University Hospital
🇯🇵Tsu, MIE, Japan
Local Institution - 0167
🇯🇵Osaka, Japan
Nihon University Itabashi Hospital
🇯🇵Itabashi-ku, Tokyo, Japan
Local Institution - 0166
🇯🇵Matsumoto, Nagano, Japan
Local Institution - 0108
🇯🇵Shinjuku, Tokyo, Japan
Polyclinic of Private Security Personnel
🇷🇺Saint Petersburg, Russian Federation
Ars Vitae Multidisciplinary Medical Center
🇷🇺Saint Petersburg, Russian Federation
The Jikei University Hospital
🇯🇵Minato-ku, Tokyo, Japan
Local Institution - 0175
🇯🇵Shinjuku-Ku, Tokyo, Japan
Dermatology Specialists Research-Kentucky
🇺🇸Louisville, Kentucky, United States
Etre Cosmetic Dermatology and Laser Center
🇺🇸New Orleans, Louisiana, United States
Clinical Medical Center of Moscow State Medico-Stomatological University named after AI Evdokimov
🇷🇺Moscow, Russian Federation
Related News
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years
- Prev
- 1
- Next